EmbectavsEli Lilly and Company

EMBC and LLY stock compared: price, dividend, valuation and results, from SEC filings.

EMBC

Embecta Corp.

$5.95

Value $348M

-2.30%
EMBC's page

LLY

Eli Lilly and Company

$1,357.55

Value $1.28T

-1.84%
LLY's page

Embecta (EMBC) has a market value of $348M and Eli Lilly and Company (LLY) $1.28T. Over the last year, with dividends, EMBC moved -56.8% and LLY +32.6%. The P/E is 4.0 for EMBC and 46.4 for LLY. Dividend yield: EMBC 5.38%, LLY 0.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EMBC$348M

    LLY$1.28T

    LLY is 3,678 times EMBC

  • Revenue, 12 months

    EMBC$1.0B

    LLY$86.5B

    LLY is 85 times EMBC

  • Net income, 12 months

    EMBC$88M

    LLY$27.6B

    LLY is 315 times EMBC

  • Operating margin

    EMBC21.9%

    LLY–

  • ROIC

    EMBC20.4%

    LLY35.5%

    15.1 points apart

  • P/E

    EMBC4.0

    LLY46.4

    LLY is 12 times EMBC

  • Dividend yield

    EMBC5.4%

    LLY0.5%

    4.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EMBC-59.9%

LLY+134.0%

100200202420252026
Returns by period
PeriodEMBCWith dividendsLLYWith dividends
1 year since November 18, 2025-56.8%Price -58.1%+32.6%Price +31.8%
3 years since November 17, 2023-59.8%-26.2% a yearPrice -64.2%+134.0%+32.8% a yearPrice +129.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EMBCEmbectaLLYEli Lilly and Company

Valuation

EMBCLLY
Valuation
Price$5.95$1,357.55
Market value$348M$1.28T
Enterprise value (EV)$1.6B$1.33T
P/E4.046.4
P/E, 5-year median9.649.9
P/B–31.8
EV/EBIT7.338.1
Free cash flow yield47.3%1.5%

Results and growth

EMBCLLY
Results and growth
Revenue, 12 months$1.0B$86.5B
Net income, 12 months$88M$27.6B
Free cash flow, 12 months$165M$19.7B
Earnings per share, 12 months$1.47$30.81
Revenue growth, year on year-3.8%44.7%
Revenue growth a year, past-0.1%over 5 years+21.6%over 5 years
EPS growth a year, past-26.4%over 5 years+27.6%over 5 years

Margins and returns on capital

EMBCLLY
Margins and returns on capital
Gross margin59.0%83.6%
Operating margin21.9%–
Net margin8.6%31.9%
ROIC20.4%35.5%
ROE–88.6%

Balance sheet

EMBCLLY
Balance sheet
Cash$215M$4.9B
Total debt$1.5B$49.5B
Net debt / EBITDA4.81.2
Interest cover–38.9×

Dividends and buybacks

EMBCLLY
Dividends and buybacks
Dividend yield5.4%0.5%
Dividend per share, 12 months$0.32$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield5.4%0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EMBC or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Embecta or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.28T) is about 3,678.4 times Embecta ($348M), at today's prices.

How did EMBC and LLY stock do over the last 3 years?

Since November 17, 2023, EMBC's price moved -64.2% and LLY's +129.4%. With dividends: EMBC -59.8% (-26.2% a year), LLY +134.0% (+32.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, EMBC or LLY?

The dividend yield at today's price is 5.38% for Embecta and 0.47% for Eli Lilly and Company. Over the last twelve months they paid $0.32 and $6.34 per share.

What is the P/E of EMBC and LLY?

At today's price, the P/E is 4.0 for EMBC and 46.4 for LLY. The median of the last five years was 9.6 and 49.9, which shows where each stands against its own past.

Which has the higher profit margins, Embecta or Eli Lilly and Company?

Over the last twelve months, the net margin was 8.6% for Embecta and 31.9% for Eli Lilly and Company, and the operating margin 21.9% and –. Revenue was $1.0B and $86.5B.

Which is the better investment, Embecta or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.